Rob Lozuk, Chief Executive Officer, President, Secretary and Member Board of Directors at Syantra Inc., shared on LinkedIn:
“Yesterday’s FDA advisory committee review of GRAIL’s Galleri was an important moment for the field of cancer screening and MCED (Multi-Cancer Early Detection).
One thing that stood out: a broad MCED approach may not perform equally well across every cancer or patient population.
Breast cancer is a great example. Existing DNA-based approaches have shown more limited performance in breast cancer, particularly when the goal is detecting cancer at its earliest stages.
Syantra Inc. takes a fundamentally different scientific approach.
The Onco-ID platform is a simple blood test that uses mRNA to detect changes in the body associated with cancer, rather than looking for cancer DNA directly.
In early-stage breast cancer, very little tumor-derived DNA may reach the bloodstream, creating a significant challenge for DNA-based detection.
Our solution is designed to complement existing screening where there are known gaps.
We’re initially focused on women with dense breast tissue, where mammography can have significant limitations, and ultimately for women who aren’t being adequately screened.
The GRAIL discussion also highlighted the importance of demonstrating clinical value in clearly defined populations with meaningful unmet needs.
That’s exactly what Syantra’s ongoing clinical utility study and commercial early access programs are designed to investigate.
The goal isn’t to replace screening. It’s to make screening better and more accessible for the patient populations that need it most.
That’s what we’re working toward at Syantra.”
Other articles about Breast Cancer on OncoDaily.